Company news
Eikon Therapeutics, Inc. (NASDAQ:EIKN) news
Eikon Therapeutics, Inc. news releases on 6ix. Latest, Sep 3, 2026: Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President…
Press releases & updates
Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer
September 3, 2026
Eikon Therapeutics to Participate in Investor Conferences in September 2026
August 26, 2026
Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald
August 18, 2026
Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
August 13, 2026
Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma
August 11, 2026
Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to its Scientific Advisory Board
August 10, 2026
Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer
July 27, 2026
Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress
July 19, 2026
Eikon Therapeutics to Join the Russell 3000 Index
June 26, 2026
Eikon Therapeutics to Join the Russell 3000® Index
June 25, 2026
Eikon Therapeutics Announces the Appointment of Ma. Fatima D. Francisco to its Board of Directors
June 8, 2026
Eikon Therapeutics : Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology
May 21, 2026
Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates
May 11, 2026
Eikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Updates
March 30, 2026
Eikon Therapeutics Announces Pricing of Upsized Initial Public Offering
February 3, 2026